Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 241 results
Press release cover image

Oct 14, 2026

Colossal Accelerates the Full Dodo De-extinction Pipeline

New AI platform GenoMorph identifies candidate regulatory DNA linked to the dodo's distinctive craniofacial anatomy, while technologies adapted from earlier species programs advance Nicobar pigeon germ-cell development, chicken stem-cell chimeras and embryo gene editing.DALLAS, Oct. 14, 2026 /PRNewswire/ -- Colossal Biosciences, the world's first de-extinction company, today announced new scientific milestones that will accelerate dodo de-extinction efforts. Building on last year's advances in p
Press release cover image

Oct 14, 2026

Delve Bio Expands Metagenomic Infectious Disease Testing with Launch of Delve Detect Plasma at IDWeek 2026

New blood-based pathogen test enables unbiased detection of more than 68,000 bacteria, fungi, DNA and RNA viruses, and parasites with next-day results.IDWeek presentations highlight Delve Detect’s impact on clinical diagnosis, treatment, and management of patients with challenging infections.BOSTON--(BUSINESS WIRE)--#IDweek--Delve Bio, Inc., a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced the launch of Delve Detect Plasma, exp
Press release cover image

Oct 14, 2026

Partillion Nanovials to Support $2.5M CIRM-Funded Study of CAR T Cell Potency

USC-led research will combine high-dimensional flow cytometry with Nanovial-based Cell-Cell-seq to study how individual CAR T cells respond when they encounter their targets LOS ANGELES, CA / ACCESS Newswire / October 14, 2026 / Partillion Bioscience today announced that its Nanovial technology will be used in a USC-led research project supported by a $2.5 million California Institute for Regenerative Medicine (CIRM) Discovery Award. The project is led by Mohamed Abou-el-Enein, M.D., Ph.D., of t
Press release cover image

Oct 14, 2026

GeneCentric Announces Oral Presentation at ASHG 2026 Highlighting Fragmentomics-based ExpressCT™ Liquid Biopsy Technology

DURHAM, N.C., Oct. 14, 2026 (GLOBE NEWSWIRE) -- GeneCentric, a company making precision medicine more precise by bringing gene expression biology to liquid biopsy, today announced that it will present at the American Society of Human Genetics (ASHG) 2026 Annual Meeting taking place in Montréal, Canada from October 20-24. The oral presentation will highlight how GeneCentric’s ExpressCT™ liquid biopsy technology is able to obtain new clinically actionable signals from existing hybrid capture seq
Press release cover image

Oct 14, 2026

Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 13, 2026 /PRNewswire/ -- Likang Life Sciences will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026, to be held October 20–22 at the ADNEC Centre in Abu Dhabi, the United Arab Emirates. Shannon Cheung, Co-Founder and Vice Chairman of Likang, will join a panel discussion titled "The Future of Cancer" on October 21 to explore advances in precision oncology and the translation of innovative cancer treatments into clinical practice.Convened by the Department
Press release cover image

Oct 14, 2026

Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 13, 2026 /PRNewswire/ -- Likang Life Sciences will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026, to be held October 20–22 at the ADNEC Centre in Abu Dhabi, the United Arab Emirates. Shannon Cheung, Co-Founder and Vice Chairman of Likang, will join a panel discussion titled "The Future of Cancer" on October 21 to explore advances in precision oncology and the translation of innovative cancer treatments into clinical practice.Convened by the Department
Press release cover image

Oct 13, 2026

Paul Stamets and Fungi Perfecti Scientists Publish First-Ever Complete Genome Assembly for Rare Agarikon Fungus in Groundbreaking Peer-Reviewed Research

OLYMPIA, Wash., Oct. 13, 2026 /PRNewswire/ -- Renowned mycologist Paul Stamets and scientists at Fungi Perfecti, LLC have reached a significant milestone in fungal research with the publication of the world's first complete genome of the rare and endangered Agarikon fungus in the peer‑reviewed scientific journal G3: Genes, Genomes, Genetics.Continue Reading The study, titled "Genomic characterization of the endangered medicinal polypore agarikon (Laricifomes officinalis syn. Fom
Press release cover image

Oct 13, 2026

Syntax Bio to Present New Cellgorithm™ Research at ISSCR iPSC 20th Anniversary Symposium in Kyoto

CHICAGO--(BUSINESS WIRE)--Syntax Bio will present new research on its Cellgorithm™ cell-programming platform at the International Society for Stem Cell Research (ISSCR) iPSC 20th Anniversary Symposium, held Oct. 20-22 at the Kyoto International Conference Center in Kyoto, Japan.The research showed that Cellgorithm differentiated human induced pluripotent stem cells (iPSC) toward pancreatic beta cell states in four days. The study also identified genetic 'gridlocks' that stall cells at intermedia
Press release cover image

Oct 13, 2026

Envisagenics Awarded $2M+ NCI SBIR Grant to Expand AI-Driven RNA Splicing Analysis Capabilities Across Oncology Portfolio

Funding will advance translational readiness across Envisagenics’ cancer-specific programs for internal development and strategic partnering NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Envisagenics, Inc., an AI-driven RNA splicing therapeutics company, announced today that it has been awarded a Small Business Innovation Research (SBIR) Direct to Phase II grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). The award will provide more than $2 million
Press release cover image

Oct 13, 2026

Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases

New offering combines whole genome sequencing, RNA analysis and ongoing reanalysis to help address diagnostic challengesALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced the launch of GenomeNext™ and GenomeReveal™, a comprehensive whole genome sequencing (WGS) solution designed to help improve diagnosis of patients with rare diseases.Many patients and families undergo years of
Press release cover image

Oct 13, 2026

Mursla Bio Publishes Peer-Reviewed Validation of Tissue-Specific Extracellular Vesicle Platform for Liquid Biopsy

Study published in Journal of Extracellular Vesicles validates platform for new class of liquid biopsy: multiomic disease biology of living cells from a chosen tissue, starting with the liverPlatform underpins FDA Breakthrough Device-designated EvoLiver™ and precision medicine programs with pharmaceutical partnersCAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Mursla Bio, a precision medicine and diagnostics company built on tissue-specific extracellular vesicles (TS-EVs), today announced publ
Press release cover image

Oct 12, 2026

Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026

– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention – – Overall detection of colorectal cancer remained consistent with test’s first version, achieving 80.4% sensitivity at 90% specificity – BRISBANE, Calif., Oct. 11, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based tests, today announced the company will present l